#Hormone Therapy in Acute Myeloid Leukemia Market US

[kenresearch1]

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy.  The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

[techsciresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techscimarketresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[ericvick]

Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data

Here’s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Jan. 4)

ABIOMED, Inc. (NASDAQ: ABMD)

Arvinas Inc (NASDAQ: ARVN)

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

Bioanalytical Systems, Inc. (NASDAQ: BASI)

BioNano Genomics Inc (NASDAQ: BNGO) (said its subsidiary Lineagen’s genetic tests identified novel variants in known autism risk genes)

BridgeBio Pharma Inc (NASDAQ: BBIO)

Clearpoint Neuro Inc (NASDAQ: CLPT)

Curis, Inc. (NASDAQ: CRIS)

DiaMedica Therapeutics Inc (NASDAQ: DMAC)

Eidos Therapeutics Inc (NASDAQ: EIDX) (proxy advisory firm Institutional Shareholder Services recommended Eidos merger with BridgeBio)

Endo International PLC (NASDAQ: ENDP)

Fulgent Genetics Inc (NASDAQ: FLGT)

I-Mab ADR (NASDAQ: IMAB)

Jaguar Health Inc (NASDAQ: JAGX)

Masimo Corporation (NASDAQ: MASI)

Ocugen Inc (NASDAQ: OCGN) (reacted to its Indian partner receiving conditional approval for coronavirus vaccine in the Indian market)

Organogenesis Holdings Inc (NASDAQ: ORGO)

Otonomy Inc (NASDAQ: OTIC)

PMV Pharmaceuticals Inc (NASDAQ: PMVP)

PRA Health Sciences Inc (NASDAQ: PRAH)

Precigen Inc (NASDAQ: PGEN)

Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN)

TRACON Pharmaceuticals Inc (NASDAQ: TCON)

United Therapeutics Corporation (NASDAQ: UTHR)

Vincera Pharma Inc (NASDAQ: VINC)

Vistagen Therapeutics Inc (NASDAQ: VTGN)

X T L Biopharmaceuticals Ltd (ASDAQ: XTLB)

Down In The Dumps

(Biotech Stocks Hitting 52-week Lows Jan. 4)

4D Molecular Therapeutics Inc (NASDAQ: FDMT)

Aprea Therapeutics Inc (NASDAQ: APRE)

Calithera Biosciences Inc (NASDAQ: CALA) (reported adverse outcome for the Phase 2 study of telaglenastat in patients with advanced or metastatic renal cell carcinoma)

Intercept Pharmaceuticals Inc (NASDAQ: ICPT)

Vivos Therapeutics Inc (NASDAQ: VVOS)

Stocks In Focus Moderna Gets Israeli Regulatory Nod For Coronavirus Vaccine Candidate

Moderna Inc (NASDAQ: MRNA) announced that Israel’s Ministry of Health has given authorization to import Moderna’s mRNA-1273, its vaccine candidate against the novel coronavirus. 

Story continues

“This is the third regulatory authorization for the COVID-19 Vaccine Moderna, and its first outside of North America,” said Stéphane Bancel, CEO of Moderna.

“We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”

Israel has secured 6 million doses of mRNA-1273 and first deliveries are expected to begin shortly, the company said.

The stock was up 1.14% to $113 in premarket trading. 

Roche’s Cancer Drug Combo Gets Breakthrough Therapy Designation For Lung Cancer

Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA granted breakthrough therapy designation for tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, in combination with Tecentriq for the first-line treatment of people with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations

The stock edged up 0.22% to $44 in after-hours trading.

Gritstone Oncology Rallies On Insider, Fund Buying

Gritstone Oncology Inc (NASDAQ: GRTS) shares rallied in reaction to a filing which revealed that biotech-focused hedge fund EcoR1 Capital, LLC built up a 9.9% stake in the company.

A separate filing showed Thomas Woiwode, a member of the company’s board of directors, bought 1.35 million shares in the company at $3.71 each. 

The stock was jumping 19.16% higher to $4.85 premarket Tuesday. 

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

Tonix to Collaborate With Massachusetts General Hospital For Organ Transplant Rejection Treatment

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced the signing of a second research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets the CD40-ligand for the prevention and treatment of organ transplant rejection.

In premarket trading Tuesday, Tonix shares were jumping 8.39% to 78 cents.

Marker Announces Lifting of Clinical Hold On Acute Myeloid Leukemia Study

Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA lifted the partial clinical hold on its Phase 2 trial investigating the safety and efficacy of MT-401, its lead, multi-tumor-associated, antigen-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia.

BioXcel Says BXCL501 Aces Phase 1b/2 Study In Treating Dementia-Related Agitation

BioXcel Therapeutics Inc (NASDAQ: BTAI) said its BXCL501, an orally dissolving thin film formulation of dexmedetomidine, met the primary and secondary endpoints of the TRANQUILITY Phase 1b/2 trial that evaluated the pipeline asset at the 60 mcg dose level for treating agitation related to dementia, including Alzheimer’s disease.

Topline results from the evaluated doses showed that BXCL501 was generally well-tolerated, with rapid and durable reductions observed in measures of acute agitation with the 60 mcg dose. 

The stock was moving up 7.77% to $56.31 in premarket trading Tuesday.

Myovant’s Recently Approved Prostate Cancer Treatment Now Available In US

Myovant Sciences Ltd (NYSE: MYOV) announced the U.S. commercial availability of Orgovyx, the first and only oral gonadotropin-releasing hormone receptor antagonist approved by the FDA, for the treatment of adult patients with advanced prostate cancer.

In premarket trading Tuesday, Myovant shares were adding 3.06% to $25.59. 

Checkmate Names Pharma Industry Veteran Robert Dolski As CFO

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) announced the appointment of biopharma industry veteran Robert Dolski as its chief financial officer.

The company also said it recently strengthened its leadership team by naming Katherine Eade as General Counsel.

aTyr’s Lead Candidate Aces Midstage Study In Hospitalized COVID-19 Patients

aTyr Pharma Inc (NASDAQ: LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation.

The trial met its primary endpoint of safety, demonstrating that a single, intravenous dose of ATYR1923 was generally safe and well-tolerated in both the 1.0 and 3.0 mg/kg treatment groups, with no drug-related serious adverse events, the company said.

“We are very encouraged by the signal of clinical activity seen in the 3.0 mg/kg cohort of ATYR1923. The relatively faster time to recovery seen by adding a single dose of ATYR1923 to standard of care treatment and the greater proportion of patients recovering within a week compared to placebo give us further confidence in this signal,” said Sanjay Shukla, CEO of aTyr.

The stock was up 6.8% premarket at $4.24. 

Zosano Requests FDA Meeting On Migraine Drug Application

Zosano Pharma Corp (NASDAQ: ZSAN) said on Dec. 30 that the company requested a Type A meeting with the FDA.

The purpose of the Type A meeting is to receive FDA input on the requirements for the resubmission of the NDA for its migraine treatment candidate Qtrypta following the complete response letter received on Oct. 20.

The FDA typically responds to a sponsor’s request for a Type A meeting, if granted, with a meeting scheduled within 30 days from the receipt of the request.

Zosano shares were trading 42.93% higher at 83 cents premarket Tuesday. 

Cerecor Announces Positive Results Phase 2 Study Of CERC-002 In Hospitalized COVID-19 Patients

Cerecor Inc (NASDAQ: CERC) announced positive results from its exploratory, Phase 2 U.S.-based proof of concept trial of the human anti-LIGHT monoclonal antibody CERC-002 in hospitalized patients with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.

The trial demonstrated robust improvement in the primary endpoint — the proportion of patients alive and free of respiratory failure over the 28-day study period — compared to placebo.

The stock was jumping 24.62% to $3.29 in premarket trading Tuesday.

ImmunoGen Insiders Buy Shares

ImmunoGen, Inc. (NASDAQ: IMGN) shares moved to the upside after a series of filings revealed purchase of the company’s shares by company insiders.

In after-hours trading, the stock gained 5.93% to $6.88.

Puma Biotechnology Shares Drop On Insider Selling

Puma Biotechnology Inc (NASDAQ: PBYI) shares came under pressure after a SEC filing on Form 4 revealed that its CEO Alan Auerbach sold 355 shares in the company at $11.656 per share. A separate filing showed that Richard Bryce, the company’s chief medical and scientific officer sold 92 shares at a price of $11.65 per share.

The stock shed 5.52% to $9.76 in after-hours trading.

Offerings

Generation Bio Co (NASDAQ: GBIO) said in a filing it plans to offer 7.5 million shares of its common stock in a follow-on offering.

In after-hours trading, the stock slipped 4.42% to $28.75.

Fate Therapeutics Inc (NASDAQ: FATE) said it has commenced an underwritten public offering of $350 million in shares of common stock.

The company said it intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical R&D, and for general corporate purposes.

The stock was down 4.10% to $86 in after-hours trading.

Prelude Therapeutics Inc (NASDAQ: PRLD) said it has commenced a public offering of 1.75 million shares of its common stock in a follow-on offering. All shares of common stock to be sold in the offering will be sold by the company.

NGM Biopharmaceuticals Inc (NASDAQ: NGM) said it has commenced an underwritten public offering of $100 million in shares of its common stock. All of the shares in the proposed offering will be sold by the company.

In after-hours trading, the stock fell 2.63% to $28.48.

On The Radar Clinical Readouts

Mersana Therapeutics Inc (NASDAQ: MRSN) is scheduled to release updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. The presentation is due at the company’s virtual analyst and investor event.

Related Link: SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[marketreasearch]

Global Acute Myeloid Leukemia Market (Covid 19 Update) Overview by Type, Technological Advancements & Forecast to 2027

Global Acute Myeloid Leukemia Market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Market Analysis and Insights: Global Acute Myeloid Leukemia Market

Global acute myeloid leukemia market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

To Remain ‘Ahead’ Of Your Competitors, Request for a FREE Sample Here @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acute-myeloid-leukemia-market

Competitive Landscape and Global Acute Myeloid Leukemia Market Share Analysis

Acute myeloid leukemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acute myeloid leukemia market.

The major players covered in the acute myeloid leukemia market are Novartis AG, Teva Pharmaceutical Industries Ltd, Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc, Mylan N.V, F. Hoffmann-La Roche Ltd, and Johnson & Johnson Services, Inc., among others.

The factors propelled the growth of acute myeloid leukemia market are rise in cases of acute myeloid leukemia across the world would influence the demand of novel drugs for acute myeloid leukemia. In addition, high adoption of immunotherapy, rich pipeline and favourable reimbursement scenario are considered as a positive indicator for growth of acute myeloid leukemia. It is assumed that market for acute myeloid leukemia is majorly hampered by high treatment cost coupled with halt of late stage clinical trials.

Acute myeloid leukemia is a type of haematological cancer originates from blood-forming cells of the bone marrow. In acute myeloid leukemia, the abnormal white blood cells are formed rapidly and get accumulate in the bone marrow and eventually affects the healthy blood cells.

Global Acute Myeloid Leukemia Market Scope and Market Size

Acute myeloid leukemia market is segmented on the basis of treatment type, route of administration, end-users and distribution channel.

Based on treatment type, the acute myeloid leukemia market is segmented into chemotherapy, targeted therapy, hormone therapy, immunotherapy and others

Route of administration segment for the acute myeloid leukemia market is categorized into oral, parenteral and others

On the basis of end-users, the acute myeloid leukemia market is segmented into hospitals, homecare, specialty clinics and others

On the basis of distribution channel, the acute myeloid leukemia market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries)@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acute-myeloid-leukemia-market

Global Acute Myeloid Leukemia Market Country Level Analysis

Acute myeloid leukemia market is analysed and market size information is provided by country, treatment type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global acute myeloid leukemia market report is U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America. Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe. China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific. Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Based on geography, North America holds the major market share for acute myeloid leukemia market throughout the coming years followed by Europe owing to the rise cases of acute myeloid leukemia and favourable government policies as well as advanced healthcare facilities. Asia-Pacific is emerged as the fastest growing regional segment in terms of revenue due to the increase government initiatives and rapidly increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-acute-myeloid-leukemia-market

Patient Epidemiology Analysis

Acute myeloid leukemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

[market-insights-dbmr]

Global Orphan Drug Market 2019 Worldwide Robust Expansion by Top Key Manufactures, Overview, Size, Share, Trends, Segments, Demand and Forecast to 2025

Global orphan drug market is rise gradually to an estimated value of USD 326.25 billion by 2026 registering a CAGR of 8.5% in the forecast period of 2019-2026. Growing number of orphan diseases, accelerating novel therapies and orphan drug development programs and exclusive incentives from the government are the key factors for market growth.

Get Sample Copy Of This Report @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-orphan-drugs-market

Few of the major competitors currently working in the global  orphan  disease market are F. Hoffmann-La Roche Ltd.,  Novartis AG, Pfizer Inc., AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated (US)  and among others.

Key Developments in the Market:

In August 2018, Kyowa Hakko Kirin Co., Ltd received the FDA approval for Poteligeo (mogamulizumab-kpkc) injection, an Orphan Drug, for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome which are the types of non-Hodgkin lymphoma

In August 2018, Takeda Pharmaceutical Company Limited received FDA approval for Takhzyro (lanadelumab-flyo) injection for the treatment to hereditary angioedema (HAE) attack in patients 12 years of age and older

In June, 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of hypoparathyroidism. TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone

Competitive Analysis:

Global orphan drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of orphan drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-orphan-drugs-market

Segmentation: Global Orphan Drug Market

By Disease Type

(Oncology disease, Metabolic Disease, Hepatology, Immunology, Infection, Neurology and Others),

Drug Type

(Biological, Non-Biological, and Others),

Indication Type

(Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Renal Cell Carcinoma and Others),

Drug class

(Lenalidomide, Rituximab, Glatiramer Acetate, Nivolumab, Interferon Beta-1a, Ibrutinib, Cinacalcet Hydrochloride, Imatinib Mesylate, Bortezomib, Sodium Oxybate and Others),

Therapy Type

(Medication, Surgery and Others),

Route of Administration

(Oral, Intravenous and Others),

End- users

(Hospitals, Homecare, Specialty Clinics, Others),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Get Full Table Of content @   https://www.databridgemarketresearch.com/toc/?dbmr=global-orphan-drugs-market

Contact:

Data Bridge Market Research Tel: +1-888-387-2818 Email: Corporatesales@databridgemarketresearch.com

[helloancycruzworld]

RAC Beta Serine/ Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2. 7. 11. 1) Pipeline H1 2017 Review Market Landscape and Top Companies Analyzed Report

Description:

According to the recently published report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2017'; RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310024 .

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.

The report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2017' outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Browse the full report @ http://www.orbisresearch.com/reports/index/rac-beta-serine-threonine-protein-kinase-protein-kinase-akt-2-or-protein-kinase-b-beta-or-rac-pk-beta-or-akt2-or-ec-2-7-11-1-pipeline-review-h1-2017 .

It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Prostate Cancer, Thymoma (Thymic Epithelial Tumor), Anal Cancer, Brain Cancer, Colon Cancer, Congenital Vascular Malformation, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemias, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease, Soft Tissue Sarcoma and Solid Tumor.

Scope - The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)targeted therapeutics and enlists all their major and minor projects - The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics

Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310024 .

Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned Almac Discovery Ltd ArQule Inc AstraZeneca Plc Bayer AG Critical Outcome Technologies Inc Merck & Co Inc Novartis AG

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +912064101019

For more information contact sales@orbisresearch.com

[kenresearch1]

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

[techsciresearch]

Plasma Protein Therapeutics Market to Grow with Increasing Targeted Diseases During the Forecast Period | TechSci Research

Rapidly advancing medicinal projects are driving the growth in the global plasma protein therapeutics market in the forecast period.

According to TechSci Research report, “Global Plasma Protein Therapeutics Market By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others), By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others), By Region, Competition Forecast & Opportunities, 2026”, the global plasma protein therapeutics market is anticipated to grow with an impressive CAGR in the forecast period, 2022-2026, on the account of increased demand of effective and efficient treatment therapeutics for the chronic diseases. Moreover, the demand for the treatment is fulfilled by the research and development carried out for the technologically advanced medicine, as well as advanced administrating devices that are influencing the growth of the market in the future five years. Government support to the research and development institutes, along with the favorable investment policies are driving the growth of the market in the future five years. Also, geriatric population is more susceptible to the cardiovascular as well as neurological diseases. Plasma protein therapeutics are widely used for the treatment of these diseases, thus increasing geriatric population is enhancing the chances of the market growth in the future.

Plasma protein therapeutics include biologic medicinal procedures that are used to treat a range of rare, life threatening, chronic and genetic diseases. These therapies are of various types like immunoglobulin therapy, albumin therapy, plasma derived clotting factor, fibrinogen, etc. All these therapies involve the extraction and separation of the required biomolecule from the blood plasma that is recovered from the already infected and cured patient. These biomolecules are efficiently responsible for the treatment of the respective chronic, targeted, and other threatening disorders.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Plasma Protein Therapeutics Market"

https://www.techsciresearch.com/report/plasma-protein-therapeutics-market/7431.html

The global plasma protein therapeutics market is segmented by product, application, end user, competitional landscapes, and regional distribution. Based on application, the market is further bifurcated into hemophilia, primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura (ITP), and others. Hemophilia is an inherited genetic disorder, that renders the human body’s ability to make blood clots and therefore is unable to stop bleedings in case of incision wounds, or any tearing and rupture of epidermal cells. Primary immunodeficiency disorder (PID) is anticipated to hold the largest shares of the market in the forecast years. The market segment is anticipated to dominate the market on the backbone of increased expansion of clinical application for immunoglobulins, approval of SCIGs, and high treatment costs. Primary immunodeficiency diseases include more than 200 rare, chronic diseases that result from a defect in the immune system. The surge in demand is due to these chronic diseases.

Companies holding major shares of the global plasma protein therapeutics market include CSL Behring LLC, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, Kedrion S.P.A., China Biologics Products Holdings, Inc., Takeda Pharmaceutical Company Ltd., Baxter International Ltd., Bio Products Laboratory Ltd., ADMA Biologics, Inc., Pfizer Inc., Ferring BV, HEMA Biologics LLC, among others.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7431

Customers can also request for 10% free customization on this report.

“North America is the maximum potential market for the next five years with patient pool, availability of well-developed infrastructure for storing, and maintaining high-quality source plasma. Moreover, the healthcare industry in the region is of excellent quality and thereby the region is leading in terms of largest market for plasma protein therapeutics. Also, the FDA approvals, and research and development of the technologically advanced drugs is being carried out in the same region. Europe region is also expected to hold the significant share of the market owing to the number of market giants available in the region. Asia Pacific is anticipated to be of some significance owing to various research and developments being carried out. Moreover, the economies like China and India provide cheaper medical services thus, medical tourism might influence the market growth in the Asia Pacific region,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Plasma Protein Therapeutics Market, By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others), By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global plasma protein therapeutics and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global plasma protein therapeutics market.

Browse Related Reports:

Global Gastric Cancer Therapeutics Market, By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), By Molecule Type (Small Molecule, Biologics), By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy) By Mode of Action (Programmed Cell Death Protein 1 Inhibitors, Human Epidermal Growth Factor Receptor Antagonists, Vascular Endothelial Growth Factor Receptor Antagonists, Others), By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/gastric-cancer-therapeutics-market/7403.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techscimarketresearch]

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.

Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.

Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.

Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.

Browse Related Reports:

Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techsciresearch]

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.

Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.

Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.

Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.

Browse Related Reports:

Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[helloancycruzworld]

Global Market Study On Phosphatidylinositol 4, 5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4, 5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2. 7. 1. 153) - Pipeline Review, H1 2017

Description:

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin-receptor substrate (IRS) proteins. It is required for lymphatic vasculature development, different signaling pathways for stable platelet adhesion and aggregation. It plays an important role in platelet activation.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310025 .

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology and Ophthalmology which include indications Solid Tumor, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Lymphoma, Ovarian Cancer, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Relapsed Chronic Lymphocytic Leukemia (CLL), Squamous Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colorectal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Thrombocythemia Myelofibrosis, Thrombosis, Thymoma (Thymic Epithelial Tumor) and Thyroid Cancer.

The latest report Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H1 2017, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse the full report @ http://www.orbisresearch.com/reports/index/phosphatidylinositol-4-5-bisphosphate-3-kinase-catalytic-subunit-beta-isoform-phosphatidylinositol-4-5-bisphosphate-3-kinase-110-kda-catalytic-subunit-beta-or-pik3cb-or-ec-2-7-1-153-pipeline-review-h1-2017 .

Scope - The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)targeted therapeutics and enlists all their major and minor projects - The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics

Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310025 .

Companies Mentioned AstraZeneca Plc Bayer AG Curis Inc GlaxoSmithKline Plc Karus Therapeutics Ltd Novartis AG PIQUR Therapeutics AG

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +912064101019

For more information contact sales@orbisresearch.com

[helloancycruzworld]

H1 2017, Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2. 7. 11. 22) Pipeline Market Landscape Review Report

Description:

According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310020 .

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Browse the full report @ http://www.orbisresearch.com/reports/index/cyclin-dependent-kinase-4-cell-division-protein-kinase-4-or-psk-j3-or-cdk4-or-ec-2-7-11-22-pipeline-review-h1-2017 .

It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Lymphoma, Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Bacterial Infections, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Leukemias, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Oropharyngeal Cancer, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.

Scope - The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics and enlists all their major and minor projects - The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310020 .

Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned Beta Pharma Inc Eli Lilly and Company FLX Bio Inc G1 Therapeutics Inc Jiangsu Hengrui Medicine Co Ltd Novartis AG Onconova Therapeutics Inc Pfizer Inc Teijin Pharma Ltd Tiziana Life Sciences Plc ViroStatics srl XuanZhu Pharma Co Ltd

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +912064101019

For more information contact sales@orbisresearch.com